How to diagnose 'persistent infection' that leads to gastritis, gastric ulcers, and gastric cancer —Helicobacter pylori ...

Enhanced-efficiency nitrogen fertilizers, the high-tech products marketed as a way to squeeze more grain out of every ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the oral Bruton's tyrosine kinase (BTK) inhibitor remibrutinib (Rhapsido, Novartis Pharmaceuticals UK) for adults with ...

The FDA approval of atacicept introduces the first BAFF/APRIL dual inhibitor for IgA nephropathy, with trial data showing significant proteinuria reduction. The approval was based on data from a ...

In “Spider-Man: Brand New Day,” Peter Parker invents new technology that could accidentally change the future of the Marvel Cinematic Universe. The tech, created after a conversation with Bruce Banner ...

Ziltivekimab failed to reduce the risk of 3-point MACE (HR, 0.99) vs placebo in adults with ASCVD, CKD, and CV inflammation. Topline data were announced from a phase 3 trial evaluating ziltivekimab in ...

The first experiment was conducted in a greenhouse using a completely randomized design with five treatments and four replications. Treatments consisted of a control (without N application), urea (Ur) ...

The global N-(n-propyl) thiophosphoric triamide (NPPT) urease inhibitor market is experiencing rapid expansion as agricultural producers seek to improve nitrogen use efficiency, reduce ...

Please provide your email address to receive an email when new articles are posted on . Iptacopan received traditional FDA approval for treating adults with immunoglobulin A nephropathy. The ...

Trials of current B cell-directed therapies and an investigational inhibitor of the alternative complement pathway demonstrate proteinuria reduction in patients with IgA nephropathy. Targeting ...

What Is Skyrizi, and Why Does It Matter? Skyrizi (risankizumab-rzaa) is a prescription biologic used to treat certain immune-mediated inflammatory conditions. It is now approved by the FDA for ...

(WO) — Clariant Oil Services has reported successful offshore deployment of its HYTREAT ECO low-dosage hydrate inhibitor technology in North Sea operations, marking what the company says is the first ...